Home/EndoLipiD Therapeutics/Agustí Soler

AS

Agustí Soler

CFO

EndoLipiD Therapeutics

Therapeutic Areas

Metabolic Cardiovascular Aesthetic

EndoLipiD Therapeutics Pipeline

Drug	Indication	Phase
EDL6D	NASH (Non-alcoholic steatohepatitis)	Preclinical
EDL81 (Ac-EDL67)	Cellulite	Preclinical

Leadership Team at EndoLipiD Therapeutics

Giacomo de Simone, PhD

David M. Selva, PhD

CSO, Board Member

Rafael Simó, MD, Prof

View full EndoLipiD Therapeutics profile